Decoy Therapeutics Targets Second-Half 2027 Trial Application
Decoy Therapeutics is targeting a second-half 2027 trial application for its pan-coronavirus candidate.
Related stories
Western Investment Raises $55.87 Million in Share Private Placement
M impact | EQUITY | Nov 03, 2026, 04:36 PM UTC
Centurion to Resume Trading and Updates on Brothers Gold Project Option
Centurion says trading will resume and provides an update on its option to acquire the Brothers Gold Project in Suriname.
M impact | EQUITY | Nov 03, 2026, 04:30 PM UTC
Western Raises Over $55.8 Million From Private Placement
Western said it raised gross proceeds of over $55.8 million upon closing a previously announced private placement.
M impact | EQUITY | Nov 03, 2026, 04:30 PM UTC
Alphabet Plans $1.5 Billion Prepaid Energy Deal, Bloomberg Reports
Bloomberg reports that Alphabet plans a $1.5 billion prepaid energy deal arranged by Goldman.
M impact | EQUITY | Nov 03, 2026, 04:29 PM UTC
US Stocks Mixed; Nasdaq Rises About 1%
The Nasdaq rose about 1%, the S&P 500 advanced and the Dow edged lower. Technology led S&P 500 sectors, while consumer staples lagged.
M impact | EQUITY | Nov 03, 2026, 04:29 PM UTC
Fiserv Reportedly Cuts 3,000 Jobs Since June
Fiserv has reduced its workforce by 3,000 employees and contractors since June, including more than 10% of its senior management team, Reuters reports.
M impact | EQUITY | Nov 03, 2026, 04:25 PM UTC